10470 Results
1

Head and neck, breast cancer research highlights AACR abstracts

April 14, 2023

University of Cincinnati Cancer Center researchers will present more than a dozen abstracts at the American Association for Cancer Research Annual Meeting 2023, held in Orlando, Florida, April 14-19, including findings that could advance treatments for head and neck and breast cancers.

3

Unlocking the mysteries of cell migration

June 6, 2022

The University of Cincinnati's Atsuo Sasaki and an international team of collaborators have been awarded a Human Frontier Science Program research grant to learn more about how cells migrate, with an ultimate goal of developing new treatments to prevent cancer growth and spread.

4

A new combination for cancer treatment

January 22, 2021

Researchers at the University of Cincinnati have tested a new combination therapy in head and neck cancer animal models to see if they could find a way to make an already effective treatment even better.

5

A new co-driver in breast cancer

March 9, 2021

University of Cincinnati researchers have discovered that cooperation between two key genes drive cancer growth, spread and treatment resistance in one particularly aggressive type of breast cancer. The good news is, though, with this knowledge, they can continue to aim their targeted treatments at these genes, singularly and together, to stop breast cancer in its tracks.

6

Learning more about how cancer affects stroke risk

October 16, 2023

A collaborative team led by University of Cincinnati, University of North Carolina and Duke University researchers is studying how specific cancers and treatments affect patients' risk of stroke.

7

Using electricity to treat cancer

April 12, 2022

The University of Cincinnati's Kyle Wang, MD, is the site principal investigator for the Trident trial, studying the effectiveness of earlier electrical treatment through Optune devices to treat glioblastomas.

8

Making pancreatic cancer treatments more effective

February 7, 2023

The National Cancer Institute (NCI) has announced an intent to fund research from the University of Cincinnati’s Andrew Waters, PhD, to better understand how to overcome treatment resistance and develop better treatments for KRAS-mutated pancreatic cancer.